Inhibitors of Discoidin Domain Receptor (DDR) Kinases for Cancer and Inflammation

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Discoidin domain receptor (DDR) tyrosine kinases (DDR1 and DDR2) possess unique extracellular domains that bind collagen.
• These receptors initiate signaling cascades via tyrosine phosphorylation.
• DDRs share homology with c-Kit and Bcr-Abl kinases, influencing inhibitor development.

Purpose of the Study:

• To explore the development of potent and specific DDR inhibitors.
• To understand the key interactions enabling DDR inhibition, such as H-bonding to Met-704.
• To review the therapeutic applications of DDR inhibitors.

Main Methods:

• Investigating the structural and sequence homology between DDRs and other kinases.
• Analyzing the binding interactions of DDR inhibitors, focusing on hydrogen bonds to Met-704.
• Reviewing existing literature on DDR inhibitor efficacy.

Main Results:

• Many inhibitors developed for c-Kit and Bcr-Abl are effective against DDRs.
• A critical interaction for many DDR inhibitors involves hydrogen bonding to Met-704 within a hydrophobic pocket.
• DDR inhibitors have demonstrated efficacy in preclinical models of various conditions.

Conclusions:

• DDR inhibitors represent a significant area of research with therapeutic potential.
• Targeting the Met-704 interaction is a key strategy for developing specific DDR inhibitors.
• DDR inhibitors show promise beyond cancer therapy, including in neurodegenerative and renal diseases.